ESMO Immuno-Oncology Congress 2019
December 11–14, 2019 / Geneva / Switzerland
AMAL Team attending
A novel approach to therapeutic vaccines
AMAL aims to tackle the obstacles for effective anti-cancer therapy by stimulating a patient’s immune system in a unique way.
First-in-class immunisation technology
KISIMA®, our unique proprietary protein-based immunisation platform is self-adjuvanting and delivers several antigens in one single vaccine.
Transforming the prospects of cancer patients
We focus on the development of viable effective cancer therapies. Our most advanced asset is ATP128, a therapeutic vaccine for the treatment of metastatic colorectal cancers.
Strategic partnerships and collaborations
Our strategy is to develop KISIMA® and its current indications in oncology through to phase II, in-house or through strategic partnerships.
Latest
News
- Boehringer Ingelheim Acquires AMAL Therapeutics, Significantly Enriching Its Cancer Immunology Portfolio with Novel Cancer Vaccines Platform 15 July 2019
- AMAL Therapeutics enters clinical collaboration with Boehringer Ingelheim to evaluate ATP128 in combination with BI754091 2 May 2019
- Amal Therapeutics to publish R&D outcomes in JCI Insight 24 April 2019
Events
Amal Therapeutics SA
c/o Fondation pour Recherches Médicales
64 av. de la Roseraie
1205 Geneva
Switzerland
